Get the Stockscreener App
1.519
0.98%
-0.011
Milestone Pharmaceuticals Inc stock is traded at $1.519, with a volume of 323.42K.
It is down -0.98% in the last 24 hours and down -30.18% over the past month.
Milestone Pharmaceuticals Inc is a biopharmaceutical company dedicated to developing and commercializing etripamil for the treatment of cardiovascular medicines. Etripamil is a calcium channel blocker developed as a rapid-onset nasal spray to be administered by the patient to treat episodes of paroxysmal supraventricular tachycardia, or PSVT. The company has an ongoing Phase 2 clinical trial for patients with atrial fibrillation experiencing a rapid ventricular rate (AFib-RVR).
See More
Previous Close:
$1.53
Open:
$1.53
24h Volume:
323.42K
Relative Volume:
0.24
Market Cap:
$81.21M
Revenue:
-
Net Income/Loss:
$-59.69M
P/E Ratio:
-1.0928
EPS:
-1.39
Net Cash Flow:
$-46.54M
1W Performance:
+4.48%
1M Performance:
-30.18%
6M Performance:
-29.53%
1Y Performance:
+13.91%
1-Day Range:
$1.50
$1.5468
1-Week Range:
$1.40
$1.555
52-Week Range:
$0.6254
$2.75
Milestone Pharmaceuticals Inc Stock (MIST) Company Profile
Name
Milestone Pharmaceuticals Inc
Sector
Industry
Phone
(514) 336-0444
Address
1111 BOUL. DR.-FREDERIK-PHILIPS, STE 420, MONTREAL, QC
Compare MIST with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MIST
Milestone Pharmaceuticals Inc
|
1.519 | 130.84M | 0 | -59.69M | -46.54M | -1.39 |
|
VRTX
Vertex Pharmaceuticals Inc
|
383.34 | 96.11B | 11.42B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
560.49 | 60.40B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
429.20 | 54.91B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
671.01 | 41.30B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
295.05 | 33.25B | 3.81B | -644.79M | -669.77M | -6.24 |
Milestone Pharmaceuticals Inc Stock (MIST) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-05-25 | Resumed | H.C. Wainwright | Buy |
| Aug-22-24 | Initiated | Rodman & Renshaw | Buy |
| Jun-20-23 | Downgrade | Jefferies | Buy → Hold |
| Apr-22-22 | Upgrade | Piper Sandler | Neutral → Overweight |
| Mar-05-21 | Initiated | H.C. Wainwright | Buy |
| Jul-29-20 | Upgrade | Oppenheimer | Perform → Outperform |
| Jul-24-20 | Upgrade | Jefferies | Hold → Buy |
| Mar-25-20 | Downgrade | Jefferies | Buy → Hold |
| Mar-24-20 | Downgrade | Oppenheimer | Outperform → Perform |
| Mar-24-20 | Downgrade | Piper Sandler | Overweight → Neutral |
| Jun-04-19 | Initiated | Oppenheimer | Outperform |
| Jun-03-19 | Initiated | Cowen | Outperform |
| Jun-03-19 | Initiated | Jefferies | Buy |
| Jun-03-19 | Initiated | Piper Jaffray | Overweight |
View All
Milestone Pharmaceuticals Inc Stock (MIST) Latest News
What drives Milestone Pharmaceuticals Inc. stock priceAchieve rapid portfolio growth with smart picks - Jammu Links News
What analysts say about Milestone Pharmaceuticals Inc. stockCapitalize on market momentum for maximum profit - Jammu Links News
Should I hold or sell Milestone Pharmaceuticals Inc. stock in 2025Consistently outstanding ROI - Jammu Links News
How many analysts rate Milestone Pharmaceuticals Inc. as a “Buy”Exponential return rates - Jammu Links News
Is Milestone Pharmaceuticals Inc. stock overvalued or undervaluedFree Daily Trading Room Entry - Jammu Links News
How volatile is Milestone Pharmaceuticals Inc. stock compared to the marketInvest confidently with actionable market data - Jammu Links News
What are the latest earnings results for Milestone Pharmaceuticals Inc.Capitalize on emerging trends for profits - Jammu Links News
What are analysts’ price targets for Milestone Pharmaceuticals Inc. in the next 12 monthsTrack high-yield stocks before they peak - Jammu Links News
What catalysts could drive Milestone Pharmaceuticals Inc. stock higher in 2025Invest confidently with advanced analysis tools - Jammu Links News
How does Milestone Pharmaceuticals Inc. compare to its industry peersMaximize your gains with professional insights - Jammu Links News
Arrowhead Pharmaceuticals, Inc. (ARWR) Secures $100M Milestone from Sarepta in RNAi Breakthrough Deal - MSN
Why Milestone Pharmaceuticals Inc. stock attracts strong analyst attentionConsistent Gain Investment Strategies Emerge - metal.it
Trading Bots Trigger Alerts on Milestone Pharmaceuticals Inc. ActivityReal Time Trade Opportunity Alerts Monitor Market Surges - metal.it
Can Milestone Pharmaceuticals Inc. hit a new high this monthSwing Setup With Technical Confirmation Explained - metal.it
RSI Suggests Rebound May Be Near in Milestone Pharmaceuticals Inc.Accurate Buy Point for Momentum Stocks Detected - metal.it
Published on: 2025-07-29 04:32:28 - beatles.ru
Arrowhead Pharmaceuticals Earns $100 Million Milestone from Sarepta Therapeutics - Business Wire
Is it the right time to buy Milestone Pharmaceuticals Inc. stockFree Capital Allocation Plans - Jammu Links News
What makes Milestone Pharmaceuticals Inc. stock price move sharplyMaximize profits with strategic stock selection - Jammu Links News
How Efficient Is Milestone Pharmaceuticals Inc. at Controlling Operating CostsFree Stock Selection - metal.it
Is Milestone Pharmaceuticals Inc. stock a good hedge against inflationFree Access to Group - metal.it
Atrial Fibrillation (AF) Pipeline Market Research Report 2025 | Insights on 10+ Companies and 12+ Drugs in the Pipeline Landscape - GlobeNewswire Inc.
Is Milestone Pharmaceuticals Inc. a good long term investmentExtraordinary earning power - printweek.in
Milestone Pharmaceuticals Inc. Stock Analysis and ForecastFree Stock Movement Tracking - Autocar Professional
Is Milestone Pharmaceuticals Inc. stock a growth or value playFree Advanced Stock Screener Access - jammulinksnews.com
Milestone Pharmaceuticals Inc Stock (MIST) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.46%
1.47%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):